SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.0001000+899.9%Aug 15 3:35 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Graham Marshman who wrote (556)8/13/1997 10:56:00 PM
From: Scott Pratho   of 1359
 
Found this to partially explain the "incantation":

interneuron.com

The AHP Agreements provide for base royalties to the Company of 11.5% of AHP's net sales (equal to the royalty required to be paid by the Company to Servier) and for "additional" royalties, ranging from a minimum of 5% of the first $50,000,000 of net sales if dexfenfluramine is not descheduled to a maximum of 12% of net sales over
$200,000,000 if dexfenfluramine is descheduled and the Company does not manufacture the finished dosage formulation of
dexfenfluramine (subject to 50% reduction if generic drug competition exceeds a market share of 10% or greater of total new
Redux prescriptions in two consecutive quarters); if the finished dosage formulation is manufactured by the Company (which
the Company currently does under an agreement with Boehringer), the maximum additional royalty is 11%.

Also found from Lehman:

Sales: <$50 mill = 5% royalty, $50-150 = 8%, >$150 = 10%

Anybody know AHP's cumulative Redux sales so far?

Scott
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News